Stock comparison
DexCom
United Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DXCM
DexCom
Market cap
$27.82B
Sector
Healthcare
UTHR
United Therapeutics
Market cap
$24.13B
Sector
Healthcare
Overall winner
DexCom DXCM
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DXCM | UTHR | Winner |
|---|---|---|---|
| Warren Buffett | 69B | 71B | UTHR |
| Benjamin Graham | 74B | 76B | UTHR |
| Philip Fisher | 75B | 76B | UTHR |
| Peter Lynch | 61C | 62C | UTHR |
| Joel Greenblatt | 58C | 46D | DXCM |
| Charlie Munger | 66B | 64C | DXCM |
| Terry Smith | 66B | 64C | DXCM |
Side-by-side metrics
| Metric | DXCM | UTHR |
|---|---|---|
| Market cap | $27.82B | $24.13B |
| P/E (TTM) | 24.6x | 19.2x |
| EV/EBIT | 25.4x | 15.2x |
| ROIC (TTM) | 18.03% | 18.81% |
| Gross margin | 61.84% | 86.58% |
| Net margin | 19.31% | 40.61% |
| Revenue CAGR 5y | 17.47% | 17.22% |
| EPS CAGR 5y | 39.82% | 29.84% |
| Debt / Equity | 0.5x | - |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DXCM leads on
- EPS CAGR 5y39.82%vs 29.84%+25%
- Market cap$27.82Bvs $24.13B+13%
UTHR leads on
- Debt / Equity-vs 0.5x+100%
- Net margin40.61%vs 19.31%+52%
- EV/EBIT15.2xvs 25.4x+40%
- Gross margin86.58%vs 61.84%+29%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.